Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RHAMMB promotes metastasis of pancreatic neuroendocrine tumor

ABSTRACT: Analysis of molecular mechanisms by which RHAMMB promote metastasis of pancreatic neuroendocrine tumor.

ORGANISM(S): Mus musculus

PROVIDER: GSE200497 | GEO | 2024/04/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MicroRNA-431 promotes metastasis of pancreatic neuroendocrine tumors by targeting DAB2IP, a RasGAP tumor suppressor

Project description:Analysis of pathways regulated by miR-431 at the mRNA expression levels in pancreatic neuroendocrine tumor cells

2019-11-21 | GSE139119 | GEO

Proteogenomic characterization of pancreatic neuroendocrine tumor

Project description:To characterize pancreatic neuroendocrine tumor at protein level, we performed mass spectromery-based proteome analysis using clinical FFPE tissue samples.

2024-07-10 | PXD034571 | Pride

MicroRNA-431 promotes metastasis of pancreatic neuroendocrine tumors by targeting DAB2IP, a RasGAP tumor suppressor

Project description:MicroRNA-431 promotes metastasis of pancreatic neuroendocrine tumors by targeting DAB2IP, a RasGAP tumor suppressor

| PRJNA578481 | ENA

Single-cell RNA-sequencing of metastatic pancreatic neuroendocrine tumor

Project description:Single-cell RNA-sequencing of metastatic pancreatic neuroendocrine tumor

| PRJNA682637 | ENA

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (tumor stages)

Project description:Pancreatic neuroendocrine tumor (PanNET) is relatively infrequent but is nevertheless metastatic. Seeking to extend a new paradigm of personalized medicine, we performed an integrative analysis of transcriptomic (mRNA and microRNA) and mutational profiles and defined three clinically relevant human PanNET subtypes. Importantly, cross-species analysis revealed two of these three subtypes in a well-characterized, genetically engineered mouse model (RIP1-Tag2) of PanNET and its cell lines. Each subtype share similarities to distinct cell types in pancreatic neuroendocrine development, features are reflected in their metabolic profiles. Subtype-specific molecular signatures metabolites are proposed to identify these subtypes. Gene expression data from different stages of RIP1-TAG2 genetically engineered PanNET mouse model RT2 mouse PanNET tumors, liver metastases, normal, hyperplastic, and angiogenic islets were dissected out or isolated. RNA was extracted and hybridized on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. The CEL files were processed using aroma.affymetrix.

2015-10-30 | E-GEOD-73514 | biostudies-arrayexpress

Affymetrix SNP 6.0 array data from neuroendocrine primary tumor and its metastasis

Project description:Reports on common mutations in neuroendocrine tumors (NET) are rare and clonality of NET metastases has not been investigated in this tumor entity yet. We selected a NET and a the corresponding lymph node and liver metastases as well as the derivative cell lines to screen for somatic mutations in the primary NET and to track the fate of genetic changes (by Affymetrix SNP 6.0 micorarray and targeted resequencing by 454 GS FLX) and during metastasis and in vitro progression. using Affymetrix SNP 6.0 Arrays. Affymetrix SNP 6.0 arrays were performed according to the manufacturer's directions on DNA extracted from cryo material or cell lines. Copy number analysis of Affymetrix SNP 6.0 arrays was performed for 4 samples. 60 samples from HapMap database were used as references for copy number inference.

2012-07-16 | E-GEOD-39371 | biostudies-arrayexpress

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (tumor stages)

2015-10-30 | GSE73514 | GEO

Transcription profiling of midgut carcinoid (neuroendocrine) primary tumors and metastasis

Project description:Gene expression profiling of midgut carcinoid (neuroendocrine) primary tumors and metastasis

2008-10-30 | E-TABM-389 | biostudies-arrayexpress

RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner

Project description:Mechanisms of neuroendocrine tumor (NET) proliferation are poorly understood and therapies that effectively control NET progression and metastatic disease are limited. We found amplification of a putative oncogene, RABL6A, in primary human pancreatic NETs (PNETs) that correlated with high level RABL6A protein expression. Consistent with those results, stable silencing of RABL6A in cultured BON-1 PNET cells revealed that it is essential for their proliferation and survival. Cells lacking RABL6A predominantly arrested in G1 phase with a moderate mitotic block. Pathway analysis of microarray data suggested activation of the p53 and retinoblastoma (Rb1) tumor suppressor pathways in the arrested cells. Specific inactivation of p53 had no effect on the RABL6A knockdown phenotype, indicating RABL6A functions independent of p53 in this setting. By comparison, Rb1 inactivation restored G1 to S phase progression in RABL6A knockdown cells although it was insufficient to override the mitotic arrest and cell death caused by RABL6A loss. Thus, RABL6A promotes G1 progression in PNET cells by inactivating Rb1, an established suppressor of PNET proliferation and development. This work identifies RABL6A as a new negative regulator of Rb1 that is essential for PNET proliferation and survival. We suggest RABL6A is a new potential biomarker and target for anticancer therapy in PNET patients. Total RNA obtained from human BON-1 PNET cells with RABL6A shRNA knockdown compared to BON-1 cells expressing control vector.

2014-07-01 | E-GEOD-53778 | biostudies-arrayexpress

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

Project description:Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous neoplasms. We used quantitative global proteomic analysis on 40 PNENs to compliment paired transcriptome data.

2021-11-30 | PXD024175 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data